Perimeter Medical Imaging's Groundbreaking Announcement
Perimeter Medical Imaging AI, Inc., recognized within the medical technology sector, has recently confirmed that their B-Series Optical Coherence Tomography (OCT) system, integrated with ImgAssist AI 2.0, will have detailed pivotal trial results introduced at an upcoming annual meeting. This event is hosted by the American Society of Breast Surgeons, a key organization in the sphere of breast surgery.
Pivotal Trial Achievements
The data from the pivotal trial showcases a statistically significant reduction in the residual cancerous tissue discovered during breast-conserving surgeries. The p-value of 0.0050, achieved in this study, underscores the importance of this technology in real-time surgical settings.
Highlighting Key Performance Indicators
In the upcoming presentation, attendees can expect to see not just the positive topline results previously reported but also new analyses. These include important secondary endpoints that will contribute to the understanding of the B-Series OCT's effectiveness. Surgeons and medical professionals will benefit greatly from this comprehensive overview.
The Presentation Details
The presentation of these trial results marks a significant milestone for Perimeter as it seeks to enhance understanding and adoption of its innovative B-Series OCT technology. The event is scheduled for the scientific session of the 26th Annual Meeting of the American Society of Breast Surgeons in Las Vegas, NV, highlighting the continuous efforts made by Perimeter in the field of oncology.
Collaboration with Medical Experts
Dr. Alastair Thompson, the Primary Principal Investigator for this pivotal trial, will lead the presentation. His extensive experience in breast surgery and as a professor adds credibility to the results being shared. Attendees will gain insights into the advancements in surgical technology that Perimeter is advocating for.
Future Implications for Breast Cancer Treatment
Perimeter's Chief Executive Officer, Adrian Mendes, expressed his enthusiasm about sharing these findings. He highlighted that the integration of an AI component aims to empower surgeons to utilize cutting-edge technology efficiently. This ensures high-resolution imaging that is crucial for accurately visualizing margins during procedures.
Regulatory Path Forward
Moreover, with their sights set on regulatory approval, Perimeter aims to submit their FDA premarket approval application early next year for the B-Series system designed specifically for breast-conserving surgeries. The pivotal trial's success plays a critical role in paving the way for this submission.
About Perimeter Medical Imaging AI, Inc.
Perimeter Medical Imaging AI operates out of both Toronto and Dallas and is dedicated to transforming cancer surgery through sophisticated imaging technologies. Their FDA-cleared Perimeter S-Series OCT provides critical insight into excised tissues, marking a significant advancement in surgical procedures.
The B-Series OCT, still under investigational use, represents the forefront of AI-enhanced imaging, potentially reshaping current practices in the fight against breast cancer. Supported by substantial funding from cancer research initiatives, this innovation is set to revolutionize surgical approaches.
Frequently Asked Questions
What is Perimeter Medical Imaging AI known for?
Perimeter Medical Imaging AI specializes in advanced medical imaging technologies, particularly for cancer surgeries, aiming to improve surgical outcomes.
What are the goals of the B-Series OCT technology?
The B-Series OCT technology aims to provide real-time imaging for surgeons, enhancing their ability to visualize and assess margins during breast-conserving surgeries.
When and where will the presentation take place?
The presentation will occur at the 26th Annual Meeting of the American Society of Breast Surgeons in Las Vegas, NV, specifically scheduled for the scientific session.
What is the significance of the pivotal trial results?
The pivotal trial demonstrated a statistically significant reduction in residual cancer during surgeries, highlighting the potential effectiveness of the B-Series OCT in clinical settings.
How does the integration of AI enhance the B-Series OCT?
The integration of AI aims to assist surgeons in efficiently utilizing the B-Series OCT technology, providing precise imaging to improve surgical outcomes.
